Lead Sponsor

Neurocrine Biosciences

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•1. Completed written informed consent.
•2. Aged 18 to 65 years, inclusive, at the time of informed consent.
•3. Primary diagnosis of MDD.
•4. Participants must meet one of the following criteria:
•* must have been taking ≥1 antidepressant medication(s) for ≥8 weeks prior to screening.
•* must have received ≥1 antidepressant medication(s) for ≥8 weeks in the current or most recent episode of depression.
•5. Snaith Hamilton Pleasure Scale (SHAPS) score is ≥30 at screening and Day 1.

•Participants will be excluded from the study if they meet any of the following key criteria:
•1. Any psychiatric disorder disallowed per protocol and electroconvulsive therapy (ECT) within 6 months prior to screening. Comorbid anxiety disorders are not exclusionary.
•2. Have a significant risk of suicidal or violent behavior.
•3. A history of seizure disorder, stroke, Alzheimer disease, Parkinson disease, multiple sclerosis, head injury associated with loss of consciousness for more than 15 minutes, or other neurodegenerative disorder.